Please assess the completion status of the following clinical trial:

Trial Title: Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must weigh at least 40 kg~* Possess the β1389 Arg/Arg genotype~* Left Ventricular Ejection Fraction (LVEF) \< 0.50 assessed within 12 months prior to Screening~* At least one episode of symptomatic paroxysmal or persistent AF within 180 days of Screening~* Clinically appropriate for electrical cardioversion (ECV) if AF/AFL is present after study drug initiation~* Receiving appropriate anticoagulation therapy prior to Randomization~Key Exclusion Criteria:~* NYHA Class IV symptoms at the time of Randomization~* Significant fluid overload at Randomization~* Permanent AF at Screening~* More than two previous ECV within 6 months of Randomization or if the most recent ECV failed to produce SR~* Presence of an LVAD, or likely to requirement LVAD placement within 6 months of Randomization~* History of a successful atrioventricular (AV) node ablation~* History of an AF/AFL ablation within 30 days of Randomization~* Evidence of an appropriate firing of an implanted cardioverter-defibrillator (ICD) device for ventricular tachycardia (VT) or ventricular fibrillation (VF) within 90 days of Randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- bucindolol hydrochloride (Type: EXPERIMENTAL): bucindolol hydrochloride (bucindolol)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; \< 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of bucindolol was 6.25 mg BID with weekly dose titrations to the weight-based target dose or to the maximum tolerated dose. The starting dose assigned was based on the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg.
- metoprolol succinate (Type: ACTIVE_COMPARATOR): metoprolol succinate (Toprol-XL)~Participants were randomized (1:1) to blinded treatment with bucindolol or metoprolol and titrated weekly to target doses of 50 mg twice daily (BID; \< 75 kg) or 100 mg BID (≥ 75 kg) for bucindolol or 200 mg once daily (QD) for metoprolol. 84% of bucindolol participants attained target dose and 72% of metoprolol participants attained target dose.~The lowest starting dose of metoprolol was 25 mg QD with weekly dose titrations to the target dose or to the maximum tolerated dose. The starting dose assigned was based upon the patient's beta-blocker treatment prior to randomization. Capsules for titration were available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).